2-Propanol (CAS 67-63-0), commonly referred to as isopropyl alcohol or IPA, is a secondary aliphatic alcohol with a molecular weight of 60.10 g/mol, a boiling point of 82.5 °C, and a closed-cup flash point of approximately 11.7 °C. In hand sanitiser applications, it functions as a topical antiseptic active ingredient when labelled to decrease microbial contamination on skin. The OTC drug status of IPA hand sanitiser—FDA establishment registration and label requirements—originates from the product’s intended use. Under 21 U.S.C. 321(g)(1)(B), an article intended to prevent disease or to affect body structure or function is a drug, and skin antisepsis claims trigger drug classification even when the vehicle is an aqueous alcohol solution. Consequently, a 2-propanol hand sanitiser is not a cosmetic under the Federal Food, Drug, and Cosmetic Act, and all establishments that manufacture, repack, relabel, or salvage the product are subject to FDA drug establishment registration, drug listing, current good manufacturing practice, and OTC labelling obligations.

Production-scale handling of IPA hand sanitiser requires explosion-resistant plant infrastructure because pure isopropanol has a closed-cup flash point below 23 °C and a vapour pressure near 4.4 kPa at 20 °C. Stainless steel 316L compounding vessels, electrically bonded transfer lines, and load cells rated for Class I flammable liquid service are standard equipment on manufacturing lines. The viscosity of pure IPA at 20 °C is approximately 2.4 mPa·s, which allows rapid liquid blending at moderate agitator tip speeds, but thickened alcohol gels present a different rheological profile and require controlled neutralization of carbomer dispersions.

What Confers OTC Drug Status on an Isopropanol-Based Hand Sanitiser?

The classification pathway begins with the 1994 tentative final monograph for consumer antiseptic rubs, which described isopropanol at a concentration of 70%–91.3% v/v as an active ingredient. Isopropanol hand sanitisers are regulated as OTC drug products because their labelling states microbial reduction or antisepsis. FDA’s 2019 final rule on consumer antiseptic rubs deferred the generally recognized as safe and effective determination for isopropanol and ethanol pending additional safety data. As a result, isopropanol-based hand sanitisers remain within the framework of unapproved OTC drugs under monograph deferral, and marketed formulations rely on the existing tentative monograph and FDA enforcement discretion policies, including the temporary policy for alcohol-based hand sanitiser preparation issued during the public health emergency. This status has direct operational consequences: absence of a final OTC monograph does not eliminate registration, listing, cGMP, or label obligations under 21 CFR Part 207, 21 CFR Part 210, 21 CFR Part 211, and 21 CFR 201.66.

Batch documentation must therefore reference the active ingredient as isopropyl alcohol or 2-propanol with a concentration that matches the drug listing. A formulation using 75% v/v IPA is common, but FDA does not currently list a single finalized monograph concentration for all isopropanol hand sanitisers under the 2019 deferral; the label claim must match the validated batch record and registration file. Gas chromatographic verification of alcohol content is performed using a flame ionization detector and a suitable capillary column, with the alcohol determination procedure commonly referenced to USP General Chapter 611. Incoming IPA quality also matters because technical-grade material can carry acetone, benzene, or nonvolatile residue that is not acceptable for pharmaceutical use without further purification or documentary justification.

The label of an OTC isopropanol hand sanitiser must use the Drug Facts format set out in 21 CFR 201.66. The “Active ingredient” field lists isopropanol with its percentage by volume, the “Purpose” field is “Antiseptic,” and the “Uses” field states that the product is used for hand sanitising to decrease bacteria on skin when soap and water are not available. Warnings must address flammability, external use only, avoidance of eye contact, discontinuation if irritation develops, and accidental ingestion. The Drug Facts box must be printed in a minimum type size tied to available label surface area under 21 CFR 201.66(d). Production audits have rejected labels when the volume statement is inserted inside the Drug Facts box, when the active ingredient is listed as “propan-2-ol” in the formulation record but as “isopropyl alcohol” in the registration file, or when the labelled IPA percentage differs from the validated batch record by 1% v/v or more.

FDA Establishment Registration Under Section 510 of the FD&C Act

Operators of domestic or foreign establishments engaged in manufacturing, repacking, relabelling, or salvaging OTC hand sanitiser containing 2-propanol must register each establishment with FDA. Registration is submitted electronically through the FDA Electronic Submissions Gateway using Structured Product Labeling format. Failure to complete annual renewal between October 1 and December 31 causes registration to lapse; import entries are then subject to refusal under 21 U.S.C. 381(a). A contract filling operation that repackages bulk IPA sanitiser into 50-mL, 59-mL, 250-mL, or 500-mL HDPE dispensing bottles must be registered separately if the filling site is geographically distinct from the compounding site. Listing data include the NDC labeler code, product name, active ingredient concentration, dosage form, package type, and manufacturing site. Production-scale audit findings frequently show discrepancies between the SPL formulation and the executed batch record, particularly when contract manufacturers substitute anhydrous IPA for 99% IPA without updating the product listing.

The annual renewal calendar is a critical bottleneck. A missed renewal can interrupt distribution until FDA processes a reactivation or new submission, and drug listings that reference inactive facilities cause import delays. FDA does not issue a certificate of approval as part of establishment registration; registration is a compliance obligation distinct from premarket approval. Contract packagers should maintain a written quality agreement specifying which party is responsible for registration, listing, and label updates. When the distributor is listed as the labeler code holder but the filler is not named as a manufacturing site, FDA inspection records frequently note the discrepancy as a listing violation under 21 CFR Part 207.

The registrant must also ensure that the US agent is identified for foreign establishments. FDA uses the US agent for correspondence and inspection scheduling. Foreign IPA hand sanitiser plants are subject to inspection under 21 U.S.C. 374, and drug cGMP compliance applies even when the product is marketed under enforcement discretion. Computerized registration and listing systems require SPL authoring software capable of encoding active ingredient concentrations and package components. Common submission failures include incompatible SPL versions, duplicate establishment records, or listing the same NDC under two different active ingredient concentrations.

When a Foreign IPA Hand Sanitiser Plant Enters the US OTC Market

A foreign manufacturer of 2-propanol hand sanitiser must designate a US agent before registration. The US agent receives correspondence and is contacted during FDA inspections. Drug establishments outside the US are also subject to drug cGMP requirements under 21 CFR Part 210 and 21 CFR Part 211. Production experience shows that import delays occur when the registration and listing reference a manufacturer but not the actual contract filler, or when the NDC labeler code is listed by the distributor instead of the manufacturer. Because IPA solutions are Class IB flammable liquids, the facility must comply with 29 CFR 1910.106 storage limitations, and transfer lines should be electrically bonded and grounded to a resistance of not greater than 1 × 10⁶ ohms to prevent static discharge. Mixers, pumps, and filling heads in areas where vapour may exceed 25% of the lower flammable limit require explosion-proof or intrinsically safe construction.

At manufacturing scale, 2-propanol hand sanitiser is compounded in 316L stainless steel vessels primarily to avoid particulate migration and iron contamination rather than corrosivity. The low viscosity of aqueous IPA permits mixing at moderate tip speeds, but gelled systems require high-shear dispersion. Carbopol thickeners, when used, require neutralizers such as triethanolamine; the addition sequence and pH endpoint have a narrow processing window. Addition of Carbopol 940 at 0.4 wt% to a 75% IPA/water system produces a shear-thinning gel, but neutralization must raise pH above 5.5 to develop full viscosity. Premature addition of neutralizer before complete polymer dispersion causes fisheye agglomerations that do not hydrate and require batch filtration. Published data for this specific configuration is limited, but production batch records commonly show viscosity loss when pH exceeds 7.5 due to ionic screening of the polymer network. Final viscosity is measured with a rotational viscometer at 20 rpm and 25 °C, with target ranges specific to the formulation rather than fixed by a single public standard.

Label and registration alignment requires the active ingredient declaration to match the validated method used for in-process alcohol determination. On automated filling lines, densitometers or inline near-infrared analyzers may verify alcohol content, but the compendial referee method remains gas chromatography. Moisture ingress during bulk storage can depress the final alcohol concentration below the declared label amount. Karl Fischer titration referenced to USP General Chapter 921 is used to verify water content. Because the 2019 GRASE deferral means no final OTC monograph concentration is codified for every formulation, label percentage should match the validated batch record and registration listing exactly. A discrepancy of 1% v/v between label and assay can constitute misbranding under 21 U.S.C. 352.